Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.

Creative Commons License

Roubaud G., Özgüroğlu M., Penel N., Matsubara N., Mehra N., Kolinsky M. P., ...Daha Fazla

European journal of cancer (Oxford, England : 1990), cilt.170, ss.73-84, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 170
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.ejca.2022.04.016
  • Dergi Adı: European journal of cancer (Oxford, England : 1990)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.73-84
  • Anahtar Kelimeler: PROfound, Metastatic castration-resistant prostate, cancer, Olaparib, Safety, Adverse-event management, RELAPSED OVARIAN-CANCER, MAINTENANCE THERAPY, MUTATION, CHEMOTHERAPY
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: Based on PROfound, olaparib is approved for patients with metastatic castration-resistant prostate cancer following disease progression on at least enzalutamide or abiraterone and who carry relevant alterations in DNA repair genes. To facilitate continued olaparib treatment as long as the patient derives benefit, we describe further safety assessments from PROfound focusing on the four most common adverse events (AEs) and events of special interest.